Markus Von Raumer

USPTO Granted Patents = 15 (Patent Applications = 6)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 16)

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 41(Granted Patents)

Company Filing History:

12 out of 77

Idorsia Pharmaceuticals Ltd

patents

2 out of 217

Actelion Pharmaceuticals Ltd

patents

1 out of 1

Viatris Asia Pacific Ptd. Ltd.

patent

Years Active: 2013-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12297189 - Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan (2025-05-13),

2. 12227532 - Crystalline forms (2025-02-18),

3. 11680058 - Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan (2023-06-20),

4. 11555025 - Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamide (2023-01-17),

5. 11365209 - Crystalline forms (2022-06-21),

6. 11339148 - Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide (2022-05-24),

7. 11059803 - Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide (2021-07-13),

8. 10919881 - Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan (2021-02-16),

9. 10730896 - Crystalline forms (2020-08-04),

10. 10351560 - Crystalline forms (2019-07-16),

11. 10023560 - Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist (2018-07-17),

12. 9914720 - Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists (2018-03-13),

13. 9790208 - Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist (2017-10-17),

14. 9062014 - Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one (2015-06-23),

15. 8492555 - Salts of isobutyric acid (1 R*, 2R*, 4R*)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester (2013-07-23),

Title: The Innovative Mind of Markus Von Raumer

Introduction

Markus Von Raumer, an accomplished inventor based in Allschwil, Switzerland, is known for his significant contributions to the field of pharmaceuticals. With 15 patents to his name, he has played a pivotal role in the development of innovative medicinal compounds, particularly in the realm of receptor antagonists. His work is characterized by a blend of scientific ingenuity and practical applications, aiming to address various medical needs.

Latest Patents

Among his latest innovations are novel crystalline forms of a 4-pyrimidinesulfamide derivative known as aprocitentan. This inventive work concerns the development of various crystalline forms of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide. The patent details not only the processes for their preparation but also their formulation into pharmaceutical compositions. These compositions are recognized for their potential as endothelin receptor antagonists, showcasing their therapeutic promise. Additionally, he has developed crystalline forms of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, underscoring their use as P2Y receptor antagonists, further reflecting his innovative capabilities.

Career Highlights

Markus has had an impactful career, having worked with prominent companies in the pharmaceutical industry. His tenure at Idorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd has allowed him to collaborate on groundbreaking projects and enhance his expertise in drug development.

Collaborations

Throughout his career, Markus has had the privilege of working alongside talented professionals, including Bibia Heidmann and Christoph Boss. Their collaboration has fostered an environment of creativity and scientific exploration, contributing to the successful development of new pharmaceutical innovations.

Conclusion

Markus Von Raumer stands out as a significant figure in the pharmaceutical field, with his 15 patents reflecting his dedication to innovation and improvement in medical treatments. His latest contributions continue to pave the way for future advancements, showcasing the importance of scientific exploration in solving complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.